Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07677059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Study acronym: BREADTH-EXT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 1 → 7 locations Start date changed from estimate of Jul 2026 to Jun 25, 2026 · Eligibility criteria expanded, about 8 words Show 2 more changesShow less
    • Start date changed from estimate of Jul 2026 to Jun 25, 2026
    • Eligibility criteria expanded, about 8 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
Trial Details
NCT Number NCT07677059
Lead Sponsor Kymera Therapeutics, Inc.
Conditions Asthma (Diagnosis)
Enrollment 264 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov